Veracyte (VCYT) exec sells 13,425 shares, 117,346 remain

Rhea-AI Filing Summary

Veracyte, Inc. executive Phillip G. Febbo reported two stock transactions on March 2, 2026. The company withheld 6,035 shares of common stock at $36.01 per share to cover his tax obligations from vesting restricted stock units, which is not a market sale. He also completed an open-market sale of 13,425 shares at a weighted average price of $36.1586 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 117,346 shares of Veracyte common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Febbo Phillip G.

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific & Med Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		F(1)		6,035	D	$36.01	130,771	D
Common Stock	03/02/2026		S(2)		13,425	D	$36.1586(3)	117,346	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on March 2, 2026 and does not represent a sale.

2. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

3. Represents weighted average sales price. Sale prices for the transactions range from $35.78 to $36.65. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Veracyte (VCYT) report for Phillip G. Febbo?

Veracyte reported that Phillip G. Febbo had 6,035 shares withheld for taxes on vested RSUs and sold 13,425 common shares in the open market. Both actions occurred on March 2, 2026, and were disclosed in a Form 4 filing.

How many Veracyte (VCYT) shares did the officer sell and at what price?

Phillip G. Febbo sold 13,425 shares of Veracyte common stock at a weighted average price of $36.1586 per share. Individual sale prices ranged from $35.78 to $36.65, according to the Form 4 disclosure footnotes.

Were any Veracyte (VCYT) shares disposed of for tax withholding purposes?

Yes. 6,035 Veracyte common shares were withheld to satisfy Phillip G. Febbo’s tax obligations tied to vesting restricted stock units. The filing clarifies that this withholding is not considered a sale into the open market.

How many Veracyte (VCYT) shares does Phillip G. Febbo own after these transactions?

Following the tax withholding and open-market sale, Phillip G. Febbo directly owns 117,346 shares of Veracyte common stock. This post-transaction balance is reported in the Form 4 as his direct ownership position.

Was the Veracyte (VCYT) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 notes that the reported transactions were made under a Rule 10b5-1 trading plan adopted by Phillip G. Febbo on August 21, 2025, providing a pre-arranged framework for executing trades over time.

What is the nature of the ‘F’ code transaction in this Veracyte (VCYT) filing?

The “F” code transaction represents shares withheld to cover tax liabilities from RSU vesting. In this case, 6,035 Veracyte shares were withheld, and the filing explicitly states this event does not represent a sale in the market.